Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS
Links shared publicly online about this topic.
- 715total visits
Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS
Bristol-Myers Squibb Company and Pfizer today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.
View full resource at news-medical.net
Tags: Stroke, Thrombotic Event, Disease and Condition, Clinical Trial, Pfizer, Bristol-Myers Squibb, News
Most Recently Shared on November 19, 2010 at 8:26 pm By:
Stroke News: Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS: Bristol-M... http://twurl.nl/hbmrnu
APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued
medicalnewstoday.com — “Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syn” View full resource at medicalnewstoday.com
Most Recently Shared on November 20, 2010 at 3:05 am By:
APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued http://mnt.to/3MTp #heart #heartdisease
Advertisement
